Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults. The Watertown, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback